Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
Inovio to advance painless device to simultaneously deliver multiple vaccines using electroporation technology.

Inovio Pharmaceuticals, Inc. has been selected to receive a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of its next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation. Inovio is collaborating with Dr. Connie Schmaljohn, Chief Scientist at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The goal of this public/private partnership is to develop a device that would facilitate rapid vaccination of U.S. troops stationed around the world against multiple infectious diseases and protect civilian populations from pandemic threats.

Dr. J. Joseph Kim, Inovio's president & CEO, said, "This new device would provide a means to rapidly and painlessly deliver multiple vaccines simultaneously to large groups of people. This collaboration builds on Inovio's strong relationship with Dr. Schmaljohn and her team at USAMRIID in which Inovio is bringing medical innovation to several biodefense efforts. Moreover, the advancements from this project will enable rapid and efficient delivery of Inovio's SynCon® vaccines for universal flu, HIV, and other infectious diseases on a mass scale."

The Inovio team of researchers has been collaborating with USAMRIID scientists to advance a DNA vaccine for the Lassa virus, which the DOD has designated as a "Category A" pathogen. In previous testing, an optimized DNA vaccine for the Lassa virus delivered by surface electroporation demonstrated complete protection against a virus challenge in both guinea pig and non-human primate disease models. Although prior results are highly encouraging and electroporation delivery is very tolerable from a patient perspective, improvements are still needed to make the technology more suitable for multiple vaccine administrations and mass vaccinations.

This NIAID grant builds on a 2011 Small Business Innovation Research Grant in which Inovio demonstrated a delivery device that was designed to deliver two separate DNA vaccines simultaneously. In this new program, Inovio will develop the multi-vaccine electroporation delivery device to address biodefense vaccine targets – notably to advance the Lassa virus vaccine through to clinical studies.

The research effort will investigate the novel simultaneous delivery of multiple DNA vaccines — final testing will use the Lassa virus and other arenaviruses — at distinct spatial sites while avoiding immune interference between vaccines. In addition, this new device platform could significantly increase the dose of vaccine delivered at one time which is a current limitation in vaccine delivery to the skin. The new skin surface device resulting from this research will leverage Inovio's latest surface DNA vaccine delivery technology, based on the company's proprietary electroporation delivery platform which uses millisecond electrical pulses to dramatically improve cellular uptake of the vaccine and resulting immune responses. Inovio vaccines delivered with electroporation devices for cancer and infectious diseases have previously demonstrated best in class T-cell and antibody responses in clinical studies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Inovio Pharmaceutical's DNA Vaccine for the MERS Virus Induces Robust Immune Response
No vaccine exists for the MERS virus that has killed 42% of those infected.
Monday, December 02, 2013
Inovio Pharmaceuticals' Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
Mice and monkey study demonstrates robust and broad immune responses.
Thursday, July 25, 2013
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Itchy Inflammation Of Mosquito Bites Helps Viruses Replicate
The itchy swelling that appears at the site of a mosquito bite isn't just an irritating nuisance - it also makes viral infections spread by the insects far worse, new research has found.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Revealing T-Cells in Action
Salk scientists show how T-cell receptors reposition during an immune response, revealing more on how the immune system is regulated.
Impact of Antibiotic Treatment on the Infant Gut Microbiome
Study shows that antibiotic treatment reduces stability and diversity of microbial population in the first three years of life.
Viruses Hack Their Host's Genome with CRISPR
A virus that infects major freshwater bacteria appears to use stolen bits of immune system DNA to highjack their hosts’ immune response.
Reclaiming The Immune System's Assault On Tumors
EPFL study shows a way to reclaim corrupted immune cells.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!